To determine whether selective COX2 inhibitor also alleviates joint structural alterations in humans with MetS-OA, we conducted a longitudinal comparison of standard knee osteoarthritis outcomes between PS-matched COX2 inhibitor users and non-selective nonsteroidal anti-inflammatory drug (NSAID) users. This evidence concerns the gene PTGS2 and osteoarthritis, knee.